NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
Bayer »18/02/2010 [Company watch]
Bayer Seeks Better Than 20% Growth in China

China’s dissemination of health care insurance throughout the country will power 20% annual growth in spending for medicines in the country, according to Liam Condon, who spearheaded Bayer AG’s (BAYRY.PK) operations in China until the end of 2009. Bayer [XETRA: BAY] itself expects to produce returns that beat the 20% rate of growth.

 
by: ChinaBio Today China’s dissemination of health care insurance throughout the country will power 20% annual growth in spending for medicines in the country, according to Liam Condon, who spearheaded Bayer AG’s (BAYRY.PK) operations in China until the end of 2009. Bayer [XETRA: BAY] itself expects to produce returns that beat the 20% rate of growth. “There’s a lot of demand [in China] that’s not being tapped at the moment,” commented Condon. “The general medicine portfolio is the most attractive. Diabetes, cardiovascular, these types of indications which are no longer so attractive in the West,” he added. Condon’s comments were published in an interview published in BusinessWeek. Ironically, even though increased insurance coverage is the driver of China’s healthcare growth, Bayer’s biggest revenue producing drug, its diabetes drug Glucobay, is not covered by insurance. However, the company’s venerable low-dose aspirin product, indicated for prevention of heart attacks, is. Until Pfizer merged with Wyeth, Bayer was the proud owner of the number one ranking among China drug companies. Last summer, Condon bragged at the ChinaBio® Partnering Forum, that China was the only country in which Bayer was number one, despite its impressive $50 billion in worldwide annual revenues. In Condon’s view, the loss of the number one ranking is not important. He believes Bayer must concentrate on sustainable growth in China and remain one of the top three China drug providers. As recognition of China’s growing important, Bayer could easily move the headquarters of a global business unit to the country “in the foreseeable future,” he said. Bayer’s reported that its Q3 revenues in China were up 22% over the year-earlier period. Glucobay, the diabetes drug, is an oral medication that treats patients with type 2 diabetes who have not progressed to insulin. The drug slows digestion of carbohydrates to prevent a surge in blood sugar following a meal. Bayer also sells Adalat for high blood pressure in China.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.